FARMACIA HOSPITALARIA最新文献

{"title":"Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases.","authors":"Juan Carlos Del Río-Valencia, Rocío Tamayo-Bermejo, Juan Diego Paradas-Palomo, Beatriz Mora-Rodríguez, Cristina López-Escola","doi":"10.1016/j.farma.2026.07.009","DOIUrl":"https://doi.org/10.1016/j.farma.2026.07.009","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to evaluate the effectiveness and safety of pembrolizumab as monotherapy in patients with Non-Small-Cell Lung Cancer and brain metastases in Real-World clinical practice at Tertiary care.</p><p><strong>Material and methods: </strong>A retrospective observational study was conducted at a tertiary hospital in Spain between August 2017 and March 2023. Adult patients with stage IV non-small-cell lung carcinoma and radiologically confirmed brain metastases who received pembrolizumab monotherapy were included. Progression-free survival, overall survival, objective response rate and treatment-related adverse events were analyzed.</p><p><strong>Results: </strong>Among 172 patients treated with pembrolizumab, 45 had brain metastases and 25 received monotherapy. Median progression-free survival was 3 months (95% confidence interval: 2.02-3.97), and median overall survival was 6 months (95% confidence interval: 4.37-7.62). The objective response rate was 24%, and the disease control rate was 40%. Treatment-related toxicity of any grade was reported in 64% of patients, with no unexpected safety signals observed.</p><p><strong>Conclusions: </strong>Pembrolizumab monotherapy showed clinical activity and an acceptable safety profile in patients with non-small-cell lung carcinoma and brain metastases treated in routine practice. Larger prospective studies are needed to optimize patient selection in this setting.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149031574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world adherence and effectiveness of lipid-lowering biological therapy in a Spanish cohort: an observational cross-sectional study.","authors":"Thais Lizondo López, Arnau Torrent Rodríguez, Natàlia Arranz Pasqual, Rubén González García, Belén López García, Patricia Carolina Pazmiño Chango, Raquel Balaguer Romeu, Dolors Soy Muner, Maite Martín Conde","doi":"10.1016/j.farma.2026.05.004","DOIUrl":"https://doi.org/10.1016/j.farma.2026.05.004","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate adherence to proprotein convertase subtilisin/kexin type 9 inhibitors in patients with primary hypercholesterolemia and dyslipidemia, identify factors influencing adherence and assess its effectiveness in reducing lipid levels.</p><p><strong>Methods: </strong>A cross-sectional observational study was conducted in a tertiary hospital. Adherence was assessed using three methods: the simplified medication adherence questionnaire, the proportion of days covered, and the visual analog scale. Demographic and clinical variables were collected, and logistic regression analysis was performed to identify factors associated with adherence. Lipid parameter changes were evaluated using Student's t-test.</p><p><strong>Results: </strong>A total of 102 patients were included. The mean age (SD) was 61 years (±10.7), and 65% (66) were males. The mean adherence rate was 79.5% using the simplified medication adherence questionnaire, 97% with the proportion of days covered, and 90.2% with the visual analog scale. Younger patients (<60 years) had significantly higher adherence (p = 0.025), while those living alone (p = 0.047) and those perceiving difficulty in medication administration (p = 0.044) showed lower adherence. LDL cholesterol levels decreased by 59.2% after one year of treatment. No significant differences were found between adherent and non-adherent patients regarding total cholesterol or LDL cholesterol reductions, but adherent patients showed a greater reduction in triglycerides (p = 0.0508).</p><p><strong>Conclusions: </strong>Adherence and effectiveness of proprotein convertase subtilisin/kexin type 9 inhibitors in real-world settings appear promising in our cohort. However, older adults, individuals living alone, and those who perceive difficulties with medication administration showed lower adherence, suggesting that targeted strategies are needed for these groups. Interventions such as patient education, close monitoring, and regular follow-up could help further optimize adherence and clinical outcomes.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148991822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Milrinone in aneurysmal subarachnoid hemorrhage: A long way ahead.","authors":"Begoña Guardiola, Jesús Antonio Sánchez-Martín, Jon Pérez-Bárcena, Juan Antonio Llompart-Pou","doi":"10.1016/j.farma.2026.08.004","DOIUrl":"https://doi.org/10.1016/j.farma.2026.08.004","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter study of cladribine in relapsing-remitting multiple sclerosis in patients over 50 years.","authors":"Maria Susana Fortes-González, Leticia Herrero-Poch, Antonio Pato-Pato, Martín Lorenzo-García, Noemí Martínez López de Castro","doi":"10.1016/j.farma.2026.07.002","DOIUrl":"https://doi.org/10.1016/j.farma.2026.07.002","url":null,"abstract":"<p><strong>Objective: </strong>Cladribine is an oral immunomodulatory drug approved for the treatment of relapsing-remitting multiple sclerosis. However, evidence regarding its use in patients over 50 years is limited. The aim of the study was to evaluate the effectiveness and safety of cladribine in patients with relapsing-remitting multiple sclerosis over 50 years in real-world clinical practice.</p><p><strong>Methods: </strong>A retrospective, multicenter open study conducted in eight hospitals in Galicia. Inclusion criteria were: age ≥ 50 years, relapsing-remitting multiple sclerosis who received treatment with cladribine oral and completed a two-year follow-up. The annualized relapse rate, disability progression, magnetic resonance imaging activity (gadolinium-enhancing lesions) and the incidence of adverse events were assessed.</p><p><strong>Results: </strong>48 patients (66.7% female with a mean age of 56.8 ± 5.7 years) were included. 79.2% of patients had received prior therapy. The annualized relapse rate significantly decreased to 0.13 and 0.14 in the first and second year, respectively (p < 0.05). Gadolinium-enhancing lesions decreased to 0.05 and 0.00 (p < 0.05). No significant disability progression was observed. Mild-to-moderate adverse events were reported in 20.8% (year 1) and 8.3% (year 2) of patients. One case of prostate cancer and one fatal sepsis were reported.</p><p><strong>Conclusions: </strong>Cladribine has demonstrated both clinical and radiological effectiveness in relapsing-remitting multiple sclerosis patients over 50 years of age, with an acceptable safety profile.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Role of the pharmacist in antimicrobial stewardship programs in critically ill patients.","authors":"Miguel Ángel Amor García, Irene Aquerreta González, Carla Bastida Fernández, Amaia Egüés Lugea, Sara Cobo Sacristán, Fernando Becerril Moreno, María Martín-Cerezuela, Esther Domingo Chiva, Tatiana Betancor García, Marta Albanell Fernández, Laura Doménech-Moral, Sara Ortiz Pérez, Aurora Fernández Polo","doi":"10.1016/j.farma.2026.04.019","DOIUrl":"https://doi.org/10.1016/j.farma.2026.04.019","url":null,"abstract":"<p><p>The design and implementation of antimicrobial stewardship programs for patients admitted to intensive care units must consider the specific characteristics of this population, including infection severity, organ dysfunction, and pharmacokinetic/pharmacodynamic alterations. The creation of a multidisciplinary team and the establishment of clear, targeted objectives are essential to improve treatment appropriateness, reduce the emergence of antimicrobial resistance, and ensure the sustainability of healthcare system. Pharmaceutical care contributes to the optimisation of antimicrobial use through antimicrobial therapy review, dose individualisation based on pharmacokinetic/pharmacodynamic parameters, and treatment monitoring, while also facilitating the development of systems for monitoring clinical outcomes, microbiology, and antimicrobial consumption.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148956821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of increased flumazenil requirements in emergency settings: A multicenter retrospective study.","authors":"Jesús Ruiz-Ramos, Jesús Ruiz-Ramos, María Borja-Cano, Adrián Plaza-Díaz, Iván Agra-Montava, Edurne Fernández de Gamarra, Milagros García-Peláez, Carmen Caballero-Requejo, Pilar Fernández-Villacañas Fernández, Irene García-Masesgosa, Cristina Calzón-Blanco, Laína Oyague, Raquel López-Martínez, Emili Vallvé-Alcón, Mariam Hijazi-Vega, Joan Ramón Romá-Mora, Emilio Salgado-García, Daniel Gómez-Costas, Ana de Lorenzo-Pinto, Margarita Prats-Riera, Ana Pons-María, Yolanda Castellanos, Cristina Puivecino Puivecino-Moreno, Marisol Samartin-Ucha, María Muñoz-García, Ana Ayestarán-Altuno, Josana Fierro-Banzo, Beatriz Calderón-Hernanz, Yolanda Ibañez-Borau, Maria Isabel Archilla-Amat, Inés Jiménez-Lozano, Cristina Toro-Blanch, Raquel Aguilar-Salmerón, Mireia Bruguera-Teixidor, Ana Revuelta-Amallo, Silvia Conde-Giner","doi":"10.1016/j.farma.2026.07.008","DOIUrl":"https://doi.org/10.1016/j.farma.2026.07.008","url":null,"abstract":"<p><strong>Introduction: </strong>Flumazenil is commonly used as an antidote for benzodiazepine overdose. However, information regarding dosing practices in hospital emergency departments remains limited. This study aimed to identify the clinical factors associated with the administration of higher flumazenil doses in the emergency department setting.</p><p><strong>Methods: </strong>This was a retrospective observational study. Adult patients treated with flumazenil in eighteen Spanish emergency departments during 2023 were included. Patient comorbidities, drugs and toxics involved in the intoxication, and the doses of flumazenil administered were recorded. A logistic regression model was used to assess factors associated with increased dosing (>0.5 mg).</p><p><strong>Results: </strong>A total of 798 patients were included [51.4 years (SD: 21.4), 457 (57.3%) female]. Benzodiazepine intoxication was confirmed in 513 cases (64.3%). In addition, 45 (8.9%) patients presented concomitant intoxication with opioids, and 117 patients (22.8%) had concurrent alcohol use. The median dose of flumazenil was 0.75 mg (range: 0.125-23.1). In 338 patients (42.4%), flumazenil was delivered via continuous infusion. In the multivariate model, a significant association with higher dose was found with age younger than 65 years [OR: 2.12 (1.50-3.00)] and chronic benzodiazepine use [OR: 1.69 (1.22-2.35)].</p><p><strong>Conclusions: </strong>Flumazenil dosing in emergency department is highly variable. Increased dose requirements were observed in younger patients and chronic benzodiazepine use.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148920371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Concordance between the theoretical and real stratification of the ability-motivation-opportunity model in patients with cardiovascular pathologies.","authors":"Cecilia Solís-Martín, Ramón Morillo-Verdugo","doi":"10.1016/j.farma.2026.08.005","DOIUrl":"https://doi.org/10.1016/j.farma.2026.08.005","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the concordance between the stratification offered by the tool included in the adaptation of the capability-motivation-opportunity model for patients with cardiovascular diseases developed by De Dios et al. 2025 and that obtained when applying it in clinical practice.</p><p><strong>Methods: </strong>Observational, cross-sectional, single-center study (January-March 2025) which included patients undergoing active treatment with proprotein convertase subtilisin/kexin type 9 inhibitors or inclisiran who attended outpatient hospital pharmacy consultations. The variables collected for stratification were demographic, clinical, pharmacotherapeutic, and socio-health variables. The adapted capacity-motivation-opportunity model in patients with cardiovascular diseases was used for stratification. The Chi-square method for a single sample was used to analyze concordance. The data were processed using the IBM-SPSS v.30 statistical program.</p><p><strong>Results: </strong>A total of 126 patients were included (median age 63.2 years (IQR = 58.9-72.5); 69.2% men). The percentages obtained were 6.3% (95% CI: 2.1-10.6%) in priority 1, 33.3% (95% CI: 25.1-41.6%) in priority 2, and 60.3% (95% CI: 51.8-68.8%) in priority 3, with theoretical distribution being 10, 30, and 60%, respectively (p = 0.342).</p><p><strong>Conclusion: </strong>There is agreement between both distributions, which supports the applicability of the tool in healthcare practice, and it can be used to prioritize resources in outpatient consultations.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148913531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Farmastock: A collaborative tool for the reuse of high-cost hospital medications in a public healthcare system.","authors":"Myriam Gallego-Galisteo, Javier Romero-Puerto, María Teresa López-Mancha, Rosa Seisdedos-Elcuaz, María José Martínez-Bautista, Esaú Aguilar-Del Valle, Francisco Sierra-García, Carmen Jiménez-de Juan, María José Gándara-Ladrón de Guevara, Jesús María Fernández-Martín, Marcelo Domínguez-Cantero, Alberto Varas-Pérez, Marta Gutiérrez-Lorenzo, Belén María Muñoz-Cejudo, Jaime Cordero-Ramos, Beatriz Tauste-Hernández, David Blánquez-Martínez, María de Las Aguas Robustillo-Cortés, Miguel Reyes-Malia, María José Barbero-Hernández, María Espinosa-Bosch, Lorenzo Villalobos-Torres, Teresa Brieva-Herrero, Cristina Mora-Herrera, Joaquín Urda-Romacho, Inmaculada Casas-Hidalgo, Elena Álvaro-Sanz, María Belén Fuentes-Ibáñez, Carlos Núñez-Ortiz","doi":"10.1016/j.farma.2026.05.006","DOIUrl":"https://doi.org/10.1016/j.farma.2026.05.006","url":null,"abstract":"<p><strong>Background: </strong>The loss of high-cost hospital medicines due to expiration represents a structural problem affecting the efficiency and sustainability of the public healthcare system. This loss is not solely the result of management inefficiencies; it is frequently driven by unpredictable changes in patient clinical evolution that lead to the suspension of previously planned treatments, particularly in oncological, haematological, and immunological conditions.</p><p><strong>Objective: </strong>To describe the economic and operational impact of the Farmastock web-based tool for the inter-hospital redistribution of high-economic impact medicines nearing expiration within the Public Health System of Andalusia (SSPA), and to analyse its evolution, its behaviour by hospital type and the perception of professional users.</p><p><strong>Methods: </strong>A retrospective observational descriptive study was conducted on transfers registered in Farmastock between July 2019 and June 2025. Descriptive indicators (volume of transfers, cost avoided, most redistributed medicines) and comparative indicators (hospital type, province, efficiency per transfer) were analysed. An anonymous structured survey of professional users was included (Annex 1).</p><p><strong>Results: </strong>A total of 1,462 transfers were registered, avoiding €5,055,822.98 in spending and redistributing 93,741 units. The most frequently transferred ATC group was antineoplastic agents. The average value per transfer was €3,458.16. District hospitals led in volume, while specialised hospitals demonstrated greater efficiency per transfer. The tool was highly valued by users and its use expanded to 27 hospitals.</p><p><strong>Conclusions: </strong>The descriptive findings suggest that Farmastock is a useful and well-valued tool associated with a positive trend in health system sustainability. Beyond the estimated economic impact, it has enabled the utilisation of medicines in exceptional clinical situations, such as palivizumab administration in paediatric patients. Future integration with artificial intelligence and corporate platforms could further amplify its impact.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148913600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How safe is occupational exposure to citostatic drugs? Results from environmental and biological monitoring.","authors":"José Ángel Lema-Atán, Elena Lendoiro, Angelines Cruz, Beatriz Bernardez, María Cobo-Golpe, Nieves Mayo, Miriam Blanco-Ces, Manuel Tourís, Ángela López-Rabuñal, Irene Zarra, Manuel López-Rivadulla, Ana de-Castro-Ríos","doi":"10.1016/j.farma.2026.06.012","DOIUrl":"https://doi.org/10.1016/j.farma.2026.06.012","url":null,"abstract":"<p><strong>Objective: </strong>Occupational exposure to cytostatic drugs has been associated with acute and chronic toxicity. Despite the publication of guidelines and measures for safety handling, contamination is still reported in most recent studies. The aim of the present work was to assess contamination of cytostatic drugs in a hospital from the North of Spain.</p><p><strong>Methods: </strong>Working surfaces from the Pharmacy and the Onco-Hematology services were tested for gemcitabine, dacarbazine, methotrexate, cyclophosphamide, doxorubicinol, doxorubicin, epirubicin, irinotecan, vinorelbine, etoposide, docetaxel and paclitaxel. Urine samples from workers were also analyzed.</p><p><strong>Results: </strong>Within the Pharmacy service, contamination was detected in 57.6% of the collected samples, with cyclophosphamide and gemcitabine being the most detected compounds. At the Onco-Hematology service, contamination was present in 32.3% of the samples collected from infusion pumps, armchairs and surrounding floors, and in all samples collected from the toilets (all positive for gemcitabine, irinotecan and paclitaxel). Low concentrations (<100 pg/cm²) were detected in ≥76% of the contaminated samples in all the locations, except for the outpatients' area bathrooms, where this value was <40%. In addition, 60.7% of vials, blisters and infusion bags sampled were contaminated. Only 2 of the 82 bracelets worn by workers showed contamination with cyclophosphamide. Finally, all the urine samples were negative.</p><p><strong>Conclusions: </strong>Despite the low levels of contamination, it is advisable to carry out monitoring campaigns to maintain workers' awareness and to take corrective actions to minimize occupational exposure.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current role of cannabis in therapeutics: A critical perspective.","authors":"Eduardo López Briz, Margarita Majem Tarruella, Inmaculada Pitarch Castellano, Jesús de Santiago Moraga, Patricia Smeyers Durá","doi":"10.1016/j.farma.2026.08.002","DOIUrl":"https://doi.org/10.1016/j.farma.2026.08.002","url":null,"abstract":"<p><p>This article offers a critical overview of the therapeutic role of cannabis and cannabinoids following their recent regulation in Spain through Royal Decree 903/2025 for the use of standardized compounded formulations. In chronic pain, cannabis is not considered a high-potency analgesic, but rather a third-line option for refractory cases, especially neuropathic pain. Its benefit is modest and acts mainly on the affective-emotional dimension of suffering rather than on the nociceptive signal itself. Regarding chemotherapy-induced nausea and vomiting, it is reserved for refractory cases; although it shows benefits compared with placebo, its efficacy is comparable to that of conventional antiemetics and it presents a less favorable toxicity profile. For spasticity in multiple sclerosis, preparations such as nabiximols reduce patients' perception of symptoms, although there is a high discontinuation rate due to lack of efficacy or adverse effects. In contrast, the use of cannabidiol in refractory pediatric epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex) is supported by the strongest evidence. The BECOME study highlights improvements that go beyond seizure reduction, positively impacting alertness, sleep, and family quality of life. Its role in other indications with weak or inconsistent evidence, such as fibromyalgia, glaucoma, anorexia, and anxiety, is also reviewed. In conclusion, although cannabis may offer certain benefits, its integration into modern clinical practice should be cautious, individualized, and carried out under strict clinical supervision. The analysis of real-world use data will undoubtedly provide valuable insights.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}